Stockreport

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue [Seeking Alpha]

Inhibrx Biosciences, Inc.  (INBX) 
PDF Ozekibart's Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-1 [Read more]